Skip to content
ANAVEX
ANAVEX
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
  • JOIN US
Search
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
  • JOIN US
View allAlzheimer's DiseaseAnavex2-73EventsNews ReleasesPDDPIPELINEPressRett Syndrome

Sigma receptors: Potential medications development target for anti-cocaine agents.

May 23, 2003

Selective M1 muscarinic agonists: failure of therapeutic strategy against Alzheimer’s disease or inappropriate tactics?

May 10, 2003

IL-10 mediates sigma-1 receptor-dependent suppression of antitumor immunity.

April 1, 2003

Anti-amnesic effect of dimemorfan in mice.

March 11, 2003

Involvement of the sigma-1 receptor in the motivational effects of ethanol in mice.

March 11, 2003

Potent sigma-1 receptor ligand 4-phenyl-1-(4-phenylbutyl)piperidine provides ischemic neuroprotection without altering dopamine accumulation in vivo in rats.

February 11, 2003

A potential antidepressant activity of SA4503, a selective sigma-1 receptor agonist.

November 11, 2002

Spreading depression: Imaging and blockade in the rat neocortical brain slice.

November 11, 2002

Enhanced antidepressant effect of sigma-1 receptor agonists in β25-35-amyloid peptide-treated mice.

August 21, 2002

Sigma receptors inhibit high-voltage-activated calcium channels in rat sympathetic and parasympathetic neurons.

June 11, 2002

Involvement of sigma receptors in the behavioral effects of cocaine: Evidence from novel ligands and antisense oligodeoxynucleotides.

June 11, 2002

Predicting the failure of amyloid-beta vaccine

May 25, 2002
1
234567891011121314151617181920212223242526272829303132333435
…3637383940…
4142
43

ANAVEX® is a trademark of Anavex®Life Sciences Corp. - 2019 All Rights Reserved

Go to Top